<DOC>
	<DOCNO>NCT00586924</DOCNO>
	<brief_summary>To administer high dose safely give patient establish safe dose base high tolerate dose clinical testing .</brief_summary>
	<brief_title>A Phase I , Multicenter Dose Escalation Study Patients With Leukemia</brief_title>
	<detailed_description>To estimate maximum tolerate dose ( MTD ) , define high dose safely administer patient , establish safe dose , base ( maximum tolerate dose ) MTD , subsequent clinical testing ( Phase 2 recommend dose ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<criteria>Subjects must meet follow criterion eligible participate study : Confirmed diagnosis HCL Measurable disease Patient 's must least 2 prior systemic therapy . There must least 2 prior course purine analog , 1 response course last &lt; 2 year , patient unacceptable toxicity purine analog . ECOG performance status 02 . Patients cancer meet eligibility criterion le 5 year disease free survival consider casebycase basis Life expectancy great 6 month , assess principal investigator Must able understand sign inform consent Must least 18 year old Female male patient must agree use approve method contraception study Stage Disease : At least one follow indication treatment : Neutropenia ( ANC &lt; 1000 cells/μL ) , Anemia ( Hgb &lt; 10g/dL ) , Thrombocytopenia ( Plt &lt; 100,000/μL ) , An absolute lymphocyte count &gt; 20,000 cells/μL , Symptomatic splenomegaly Subjects meeting follow criterion eligible participation study : History allogeneic bone marrow transplant Documented ongoing central nervous system involvement malignant disease ( history CNS involvement exclusion criterion ) Pregnant breastfeed female Patients whose plasma contain either significant level antibody CAT8015 measure ELISA , antibody neutralizes bind CAT8015 CD22 measure competition ELISA . HIV positive serology ( due increase risk severe infection unknown interaction CAT8015 antiretroviral drug Hepatitis B surface antigen positive Uncontrolled , symptomatic , intercurrent illness include limited : infection require systemic antibiotic , congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness , social situation would limit compliance study requirement . Hepatic function Serum transaminases ( either ALT AST ) bilirubin : ≥ Grade 2 , unless bilirubin due Gilbert 's disease Renal function : Serum creatinine clearance ≤ 60mL/min estimate CockroftGault formula Hematologic function : The ANC &lt; 1000/cmm , platelet count &lt; 50,000/cmm , cytopenia judge investigator due underlying disease ( i.e . potentially reversible antineoplastic therapy ) A patient exclude pancytopenia ≥ Grade 3 , erythropoietin dependence , due disease , base result bone marrow study Baseline coagulopathy great equal Grade 3 unless due anticoagulant therapy Pulmonary function : Patients &lt; 50 % predict forced expiratory volume ( FEV1 ) &lt; 50 % predict diffusing capacity carbon monoxide ( DLCO ) , correct hemoglobin concentration alveolar volume . Note : Patients prior history pulmonary illness require PFTs . FEV1 assess bronchodilator therapy . Recent prior therapy : Cytotoxic chemotherapy , corticosteroid ( except stable dos prednisone ) , whole body electron beam radiation therapy , hormonal , biologic systemic therapy , investigational therapy malignancy 3 week prior entry trial Less equal 1 month prior monoclonal antibody therapy ( i.e . rituximab ) Patients receive receive radiation therapy le 3 week prior study entry exclude providing volume bone marrow treat less 10 % also patient measurable disease outside radiation port Any history prior pseudomonasexotoxin ( PE ) immunotoxin administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>